REED ELIZABETH E

SEC source: 0001415889-25-003823 · form4-02132025_020224.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

F2 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003823 · form4-02132025_020224.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.

F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer.

SEC source: 0001415889-25-003066 · form4-02042025_080220.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,482

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-25-003066 · form4-02042025_080220.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Common Stock · 58,000 shares

Expires 2035-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-003066 · form4-02042025_080220.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,433

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-25-002004 · form4-01242025_010150.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,933

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · balance_after: Includes 737 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 29, 2024.

SEC source: 0001415889-24-023095 · form4-09092024_090911.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,633

F2 · kind: This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001415889-24-023095 · form4-09092024_090911.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,020

F1 · kind: On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.

SEC source: 0001415889-24-002283 · form4-02022024_040213.xml · nonDerivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,270

F3 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001415889-24-002283 · form4-02022024_040213.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,860

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001415889-24-002283 · form4-02022024_040213.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-01-30

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-002283 · form4-02022024_040213.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,034

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001415889-24-001801 · form4-01252024_040109.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,034

F1 · kind: This sale was made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-048256 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,096

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-23-048256 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,911

F1 · kind: On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 5,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.

SEC source: 0001209191-23-029012 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,611

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on November 23, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006436 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,436

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-23-006436 · doc4.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F4 · derivative.exercise_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

F4 · derivative.expiration_date: This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.

SEC source: 0001209191-23-006436 · doc4.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2033-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-006436 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,026

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001209191-23-005035 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,776

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-028708 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,838

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-028708 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,888

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006369 · doc4.xml · derivative · entry 5

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the Common Stock of the Issuer.

F6 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

F6 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006369 · doc4.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,840

Underlying: Common Stock · 9,840 shares

Expires not disclosed

F4 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006369 · doc4.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,360

Underlying: Common Stock · 39,360 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006369 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,788

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006369 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,138

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-005081 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,298

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003053 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,548

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003053 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,548

F1 · kind: On January 4, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.

SEC source: 0001209191-21-052078 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,548

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-052078 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,955

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.

SEC source: 0001209191-21-032316 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,455

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-032316 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,080

F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-008804 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,705

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021.

SEC source: 0001209191-21-008804 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,955

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021.

SEC source: 0001209191-21-007633 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,705

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-007633 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,380

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-21-008113 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,205

F1 · kind: (1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study.

SEC source: 0001209191-21-007026 · doc4.xml · nonDerivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,880

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-007026 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,555

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

SEC source: 0001209191-21-007026 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,055

F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study.

SEC source: 0001209191-21-005252 · doc4.xml · derivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 57,500 shares

Expires 2031-01-20

F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-005252 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,055

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-21-002595 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,055

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-21-002595 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,743

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-20-058944 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,431

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.74 to $24.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058419 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,931

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $23.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-058419 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,431

F1 · kind: On January 4, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition.